FDA approves Folotyn for peripheral T-cell lymphomas

FDA regulators have apparently given accelerated approval to Allos Therapeutics' treatment for peripheral T-cell lymphomas (PTCL), Folotyn (pralatrexate injection) for treatment of relapsed or refractory PTCLs. The drug could be available in the US as soon as October.

Folotyn becomes the first drug FDA-approved to treat PTCLs.

FDA approval comes despite a lack of convincing clinical data that the drug is effective at stopping the spread of PTCL, or that it can even extend survival. At most, Allos has shown in clinical trials that Folotyn can, among some patients, reduce tumor size.

This news shouldn't be greeted by PTCL patients or their caregivers with too much enthusiasm, since the jury should still be considered out on this drug.

Dive Deeper

ClinicalTrials.gov information concerning pralatrexate
Allos press release
Forbes story on FDA approval

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap